MFSD11

Summary

MFSD11 (major facilitator superfamily domain containing 11, HGNC:25458) is a protein-coding gene on chromosome 17q25.1, encoding UNC93-like protein MFSD11 (O43934).

Predicted to be located in membrane.

Source: NCBI Gene 79157 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 101 total — 2 pathogenic, 1 likely-pathogenic
• MANE Select transcript: NM_001242532

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25458
Approved symbol	MFSD11
Name	major facilitator superfamily domain containing 11
Location	17q25.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ22196, FLJ20226
Ensembl gene	ENSG00000092931
Ensembl biotype	protein_coding
OMIM	620346
Entrez	79157

Gene structure

Transcript identifiers

Ensembl transcripts: 35 — 27 protein_coding, 4 nonsense_mediated_decay, 2 retained_intron, 2 protein_coding_CDS_not_defined

ENST00000336509, ENST00000355954, ENST00000585584, ENST00000585692, ENST00000585865, ENST00000585958, ENST00000586622, ENST00000586689, ENST00000588031, ENST00000588460, ENST00000588647, ENST00000588670, ENST00000588768, ENST00000590070, ENST00000590393, ENST00000590514, ENST00000591864, ENST00000593181, ENST00000621483, ENST00000685175, ENST00000869882, ENST00000869883, ENST00000869884, ENST00000869885, ENST00000869886, ENST00000869887, ENST00000869888, ENST00000869889, ENST00000869890, ENST00000936724, ENST00000936725, ENST00000970443, ENST00000970444, ENST00000970445, ENST00000970446

RefSeq mRNA: 10 — MANE Select: NM_001242532 NM_001242532, NM_001242533, NM_001242534, NM_001242535, NM_001242536, NM_001242537, NM_001353017, NM_001353018, NM_001353019, NM_024311

CCDS: CCDS11750, CCDS56045

Canonical transcript exons

ENST00000685175 — 13 exons

Exon	Start	End
ENSE00000335470	76738938	76738993
ENSE00001193513	76740957	76741064
ENSE00002798994	76738119	76738448
ENSE00003538660	76754047	76754087
ENSE00003574723	76743398	76743456
ENSE00003588196	76744322	76744466
ENSE00003614303	76767386	76767451
ENSE00003633530	76769746	76769871
ENSE00003635483	76774997	76775171
ENSE00003655464	76742177	76742273
ENSE00003663838	76776406	76776541
ENSE00003786680	76741969	76742048
ENSE00003932350	76778188	76779341

Expression profiles

Bgee: expression breadth ubiquitous, 244 present calls, max score 93.31.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 25.2459 / max 234.0484, expressed in 1818 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
162903	7.7559	1758
162902	7.6289	1748
162904	3.0348	1192
162899	2.6711	1441
162898	1.8548	951
162906	1.6045	492
208383	0.5325	268
162900	0.1190	27
162901	0.0444	8

Top tissues by expression

252 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	93.31	gold quality
adrenal tissue	UBERON:0018303	90.57	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	90.13	gold quality
ileal mucosa	UBERON:0000331	89.89	gold quality
bone marrow cell	CL:0002092	89.68	gold quality
rectum	UBERON:0001052	89.28	gold quality
sperm	CL:0000019	89.23	gold quality
apex of heart	UBERON:0002098	89.15	gold quality
left testis	UBERON:0004533	89.05	gold quality
lower esophagus mucosa	UBERON:0035834	89.05	gold quality
islet of Langerhans	UBERON:0000006	89.01	gold quality
right testis	UBERON:0004534	88.96	gold quality
muscle of leg	UBERON:0001383	88.94	gold quality
right atrium auricular region	UBERON:0006631	88.87	gold quality
gastrocnemius	UBERON:0001388	88.71	gold quality
left ventricle myocardium	UBERON:0006566	88.66	gold quality
monocyte	CL:0000576	88.62	gold quality
cardiac atrium	UBERON:0002081	88.45	gold quality
leukocyte	CL:0000738	88.44	gold quality
hindlimb stylopod muscle	UBERON:0004252	88.22	gold quality
vagina	UBERON:0000996	88.18	gold quality
skin of abdomen	UBERON:0001416	87.85	gold quality
cardiac muscle of right atrium	UBERON:0003379	87.82	gold quality
skin of leg	UBERON:0001511	87.78	gold quality
tibialis anterior	UBERON:0001385	87.75	gold quality
adenohypophysis	UBERON:0002196	87.71	gold quality
testis	UBERON:0000473	87.69	gold quality
smooth muscle tissue	UBERON:0001135	87.57	gold quality
esophagus mucosa	UBERON:0002469	87.47	gold quality
mucosa of transverse colon	UBERON:0004991	87.45	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-CURD-112	yes	13.98
E-ANND-3	yes	8.22

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

39 targeting MFSD11, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-9902	99.89	69.15	2250
HSA-MIR-7162-3P	99.89	68.16	1682
HSA-MIR-12119	99.87	68.35	1653
HSA-MIR-4799-5P	99.82	70.60	2663
HSA-MIR-623	99.76	68.16	1170
HSA-MIR-132-3P	99.73	70.56	1424
HSA-MIR-212-3P	99.73	70.65	1424
HSA-MIR-4755-5P	99.71	70.34	2716
HSA-MIR-5006-3P	99.71	70.26	2728
HSA-MIR-587	99.64	70.86	2611
HSA-MIR-940	99.37	66.14	2064
HSA-MIR-6808-5P	99.31	66.23	2150
HSA-MIR-6893-5P	99.31	66.25	2119
HSA-MIR-504-3P	99.30	67.18	1745
HSA-MIR-3064-5P	99.26	66.13	1497
HSA-MIR-3085-3P	99.26	66.16	1490
HSA-MIR-6504-5P	99.26	65.95	1487
HSA-MIR-6504-3P	99.17	69.31	2891
HSA-MIR-10399-5P	99.17	69.87	2610
HSA-MIR-1253	99.12	67.08	1688
HSA-MIR-7151-3P	99.04	69.72	2370
HSA-MIR-4724-5P	98.87	67.75	1324
HSA-MIR-942-3P	98.81	69.04	876
HSA-MIR-4656	98.79	66.22	1306

Literature-anchored findings (GeneRIF, showing 1)

• Results from a study on gene expression variability markers in early-stage human embryos shows that MFSD11 is a putative marker for the 3-day, 8-cell embryo stage. (PMID:26288249)

Cross-species orthologs

21 orthologs

Organism	Symbol	Gene ID
danio_rerio	mfsd11	ENSDARG00000102828
mus_musculus	Mfsd11	ENSMUSG00000020818
rattus_norvegicus	Mfsd11	ENSRNOG00000000247
drosophila_melanogaster	CG18549	FBGN0038053
caenorhabditis_elegans		WBGENE00007774
caenorhabditis_elegans		WBGENE00009485
caenorhabditis_elegans		WBGENE00010925
caenorhabditis_elegans		WBGENE00012428
caenorhabditis_elegans		WBGENE00012535
caenorhabditis_elegans		WBGENE00012686
caenorhabditis_elegans		WBGENE00012688
caenorhabditis_elegans		WBGENE00015258
caenorhabditis_elegans		WBGENE00015260
caenorhabditis_elegans		WBGENE00015592
caenorhabditis_elegans		WBGENE00017944
caenorhabditis_elegans		WBGENE00017945
caenorhabditis_elegans		WBGENE00021448
caenorhabditis_elegans		WBGENE00021797
caenorhabditis_elegans		WBGENE00021798
caenorhabditis_elegans		WBGENE00022641
caenorhabditis_elegans		WBGENE00022643

Protein

Protein identifiers

UNC93-like protein MFSD11 — O43934 (reviewed: O43934)

Alternative names: Major facilitator superfamily domain-containing protein 11, Protein ET

All UniProt accessions (8): O43934, K7ELU3, K7EM95, K7EMP0, K7EQL2, K7ERE5, K7ES57, K7ES99

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Membrane.

Similarity. Belongs to the unc-93 family.

Isoforms (2)

UniProt ID	Names	Canonical?
O43934-1	1	yes
O43934-2	2

RefSeq proteins (10): NP_001229461, NP_001229462, NP_001229463, NP_001229464, NP_001229465, NP_001229466, NP_001339946, NP_001339947, NP_001339948, NP_077287 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR010291	Ion_channel_UNC-93	Family
IPR036259	MFS_trans_sf	Homologous_superfamily
IPR051617	UNC-93-like_regulator	Family

Pfam: PF05978

UniProt features (18 total): transmembrane region 12, sequence variant 2, chain 1, modified residue 1, glycosylation site 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O43934-F1	87.72	0.62

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 204

Glycosylation sites (1): 40

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 114 (showing top): GSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_UP, GOBP_RESPONSE_TO_FOOD, MILI_PSEUDOPODIA_CHEMOTAXIS_DN, GOBP_RESPONSE_TO_STARVATION, MARSON_BOUND_BY_FOXP3_STIMULATED, MARSON_BOUND_BY_FOXP3_UNSTIMULATED, ARNT2_TARGET_GENES, BARX1_TARGET_GENES, CHAF1B_TARGET_GENES, CIITA_TARGET_GENES, CREB3L4_TARGET_GENES, EMX1_TARGET_GENES, FOXE1_TARGET_GENES, GTF2E2_TARGET_GENES, HHEX_TARGET_GENES

GO Biological Process (2): response to food (GO:0032094), response to starvation (GO:0042594)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (1): membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
response to nutrient levels	2
response to chemical	1
response to stress	1
binding	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1010 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MFSD11	SLC61A1	Q6N075	771
MFSD11	SLC67A2	Q8NBP5	670
MFSD11	MFSD6L	Q8IWD5	651
MFSD11	SLC33A2	Q96ES6	645
MFSD11	SLC68A1	Q14CX5	642
MFSD11	SVOPL	Q8N434	640
MFSD11	SLC75A1	Q14728	625
MFSD11	MFSD12	Q6NUT3	624
MFSD11	SVOP	Q8N4V2	620
MFSD11	MFSD6	Q6ZSS7	607
MFSD11	SPNS3	Q6ZMD2	548
MFSD11	METTL23	Q86XA0	544
MFSD11	MFSD8	Q8NHS3	540
MFSD11	SPNS1	Q9H2V7	539
MFSD11	SLC71A1	Q96MC6	539

IntAct

23 interactions, top by confidence:

A	B	Type	Score
MFSD11	GJB3	psi-mi:“MI:0915”(physical association)	0.560
MFSD11	GJA8	psi-mi:“MI:0915”(physical association)	0.560
MFSD11	FXYD3	psi-mi:“MI:0915”(physical association)	0.560
MFSD11	PIK3IP1	psi-mi:“MI:0915”(physical association)	0.560
MFSD11	LAYN	psi-mi:“MI:0915”(physical association)	0.560
MFSD11	PVR	psi-mi:“MI:0915”(physical association)	0.560
MFSD11	UBE2Q1	psi-mi:“MI:0914”(association)	0.530
MFSD11	AGPAT2	psi-mi:“MI:0914”(association)	0.350
MFSD11	PLD2	psi-mi:“MI:0914”(association)	0.350
MFSD11	FXYD3	psi-mi:“MI:0915”(physical association)	0.000
MFSD11	PIK3IP1	psi-mi:“MI:0915”(physical association)	0.000
MFSD11	LAYN	psi-mi:“MI:0915”(physical association)	0.000
MFSD11	PVR	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (43): MFSD11 (Two-hybrid), SMAP2 (Affinity Capture-MS), UBE2Q1 (Affinity Capture-MS), TUBB1 (Affinity Capture-MS), MFSD11 (Affinity Capture-RNA), MFSD11 (Affinity Capture-RNA), MFSD11 (Two-hybrid), MFSD11 (Two-hybrid), PIK3IP1 (Two-hybrid), GJA8 (Two-hybrid), GJB3 (Two-hybrid), LAYN (Two-hybrid), UBE2Q1 (Affinity Capture-MS), TUBB1 (Affinity Capture-MS), TMCO1 (Affinity Capture-MS)

ESM2 similar proteins: A6QQU6, A8MRY9, B3LFA3, B8AF63, F4JKQ7, O43934, O80605, P57057, P57758, Q03411, Q0D7E4, Q10R54, Q39231, Q39232, Q3TIT8, Q4R495, Q5F3N0, Q5M7K3, Q5RCQ5, Q5RD30, Q5RKH7, Q640L2, Q67YF8, Q6A329, Q6DIT7, Q6GPQ3, Q6P499, Q6PB15, Q6YK44, Q7Z5S9, Q8AVC3, Q8BGN5, Q8BJ51, Q8GWX2, Q8GYS1, Q8H4H5, Q8NCC5, Q8VE96, Q8VEH0, Q944N8

Diamond homologs: O43934, Q4R495, Q5RCQ5, Q6DIT7, Q6PB15, Q8BJ51

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

101 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	1
Uncertain significance	69
Likely benign	5
Benign	1

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
2504111	NM_001195427.2(SRSF2):c.284C>T (p.Pro95Leu)	Pathogenic
3765039	NM_001195427.2(SRSF2):c.284C>A (p.Pro95His)	Pathogenic
998075	NM_001195427.2(SRSF2):c.284C>G (p.Pro95Arg)	Likely pathogenic

SpliceAI

3116 predictions. Top by Δscore:

Variant	Effect	Δscore
17:76736180:T:TA	donor_gain	1.0000
17:76740935:C:A	acceptor_gain	1.0000
17:76740941:T:TA	acceptor_gain	1.0000
17:76740944:ATTAT:A	acceptor_gain	1.0000
17:76740945:T:G	acceptor_gain	1.0000
17:76740947:A:AG	acceptor_gain	1.0000
17:76740947:AT:A	acceptor_gain	1.0000
17:76740948:T:G	acceptor_gain	1.0000
17:76740948:T:TA	acceptor_gain	1.0000
17:76740955:A:AG	acceptor_gain	1.0000
17:76740955:AGCAT:A	acceptor_gain	1.0000
17:76740956:G:GA	acceptor_gain	1.0000
17:76740956:GC:G	acceptor_gain	1.0000
17:76740956:GCAT:G	acceptor_gain	1.0000
17:76740956:GCATG:G	acceptor_gain	1.0000
17:76741967:A:AG	acceptor_gain	1.0000
17:76741968:G:GG	acceptor_gain	1.0000
17:76741968:GC:G	acceptor_gain	1.0000
17:76741968:GCAT:G	acceptor_gain	1.0000
17:76742050:T:A	donor_loss	1.0000
17:76742162:T:TA	acceptor_gain	1.0000
17:76742163:G:A	acceptor_gain	1.0000
17:76742175:A:AG	acceptor_gain	1.0000
17:76742176:G:GG	acceptor_gain	1.0000
17:76742176:GT:G	acceptor_gain	1.0000
17:76744317:C:CA	acceptor_gain	1.0000
17:76744319:TA:T	acceptor_loss	1.0000
17:76744320:A:AG	acceptor_gain	1.0000
17:76744320:A:C	acceptor_loss	1.0000
17:76744321:G:GG	acceptor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000020615 (17:76793764 T>C), RS1000061451 (17:76793936 A>G), RS1000108320 (17:76745988 T>C,G), RS1000117888 (17:76739962 C>G), RS1000130835 (17:76758192 A>T), RS1000196998 (17:76786402 A>G), RS1000212375 (17:76774554 T>C), RS1000213558 (17:76799811 AG>A), RS1000229626 (17:76739708 C>T), RS1000300889 (17:76787004 G>A), RS1000311884 (17:76746311 G>A,C,T), RS1000338311 (17:76739870 C>G,T), RS1000369404 (17:76767522 A>G), RS1000409899 (17:76736096 C>G,T), RS1000447873 (17:76756604 T>C)

Disease associations

OMIM: gene MIM:620346 | disease phenotypes: MIM:601626

GenCC curated gene-disease

Mondo (3): atypical chronic myeloid leukemia, BCR-ABL1 negative (MONDO:0004653), acute myeloid leukemia (MONDO:0018874), acute megakaryoblastic leukemia in down syndrome (MONDO:0020526)

Orphanet (3): Acute myeloid leukemia (Orphanet:519), Atypical chronic myeloid leukemia (Orphanet:98824), Acute megakaryoblastic leukemia in children with Down syndrome (Orphanet:99887)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST002071_2	Retinal arteriolar caliber	2.000000e-10

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004731	eye measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D015470	Leukemia, Myeloid, Acute	C04.557.337.539.275; C15.378.508.539.275

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

21 total (human), top 21 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression	3
sodium arsenite	decreases expression, increases abundance, increases expression, affects cotreatment	2
FR900359	increases phosphorylation	1
bisphenol F	affects cotreatment, increases methylation	1
triphenyl phosphate	affects expression	1
beta-lapachone	increases expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
K 7174	increases expression	1
ICG 001	increases expression	1
bisphenol S	decreases methylation	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Acetaminophen	increases expression	1
Arsenic	affects cotreatment, decreases expression, increases abundance	1
Manganese	affects cotreatment, decreases expression, increases abundance	1
Quercetin	increases expression	1
Cyclosporine	increases expression	1
Aflatoxin B1	increases methylation	1
Asbestos, Crocidolite	decreases expression	1
Cadmium Chloride	increases expression	1
Acrylamide	increases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D4G9	HCT116-MFSD11-KO-c16	Cancer cell line	Male
CVCL_D4GA	HCT116-MFSD11-KO-c17	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00199147	PHASE4	UNKNOWN	Efficacy of G-CSF-Priming in Elderly AML Patients
NCT00304447	PHASE4	COMPLETED	Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia
NCT00464217	PHASE4	COMPLETED	Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years
NCT00487448	PHASE4	COMPLETED	SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia
NCT00488709	PHASE4	COMPLETED	Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT00686543	PHASE4	COMPLETED	Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)
NCT01041040	PHASE4	COMPLETED	LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)
NCT01198054	PHASE4	TERMINATED	LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)
NCT01200355	PHASE4	COMPLETED	Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome
NCT01347996	PHASE4	COMPLETED	Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia
NCT01587430	PHASE4	UNKNOWN	3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia
NCT01819792	PHASE4	COMPLETED	Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia
NCT02024308	PHASE4	UNKNOWN	AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy
NCT02027064	PHASE4	UNKNOWN	Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT
NCT02277847	PHASE4	UNKNOWN	Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia
NCT02386800	PHASE4	ACTIVE_NOT_RECRUITING	CINC424A2X01B Rollover Protocol
NCT02926586	PHASE4	COMPLETED	Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML
NCT02933333	PHASE4	UNKNOWN	G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor
NCT03026842	PHASE4	UNKNOWN	Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21)
NCT03150134	PHASE4	UNKNOWN	Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients
NCT05144243	PHASE4	ACTIVE_NOT_RECRUITING	Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China
NCT06370000	PHASE4	RECRUITING	Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality
NCT06571825	PHASE4	RECRUITING	RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR
NCT07016165	PHASE4	RECRUITING	Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies
NCT07044687	PHASE4	RECRUITING	Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India
NCT07486713	PHASE4	RECRUITING	Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
NCT07561892	PHASE4	RECRUITING	Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).
NCT00000589	PHASE3	COMPLETED	Trial to Reduce Alloimmunization to Platelets (TRAP)
NCT00044486	PHASE3	COMPLETED	Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899)
NCT00093990	PHASE3	COMPLETED	Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT00125606	PHASE3	TERMINATED	Phase 3 Trial for AML Patients in CR2 Comparing 8Gy TBI /Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide
NCT00136084	PHASE3	COMPLETED	Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
NCT00146120	PHASE3	COMPLETED	Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result
NCT00150878	PHASE3	TERMINATED	Standard vs. Reduced-Intensity Conditioning in Patients With Acute Myeloid Leukemia in First Remission
NCT00151255	PHASE3	COMPLETED	All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00152139	PHASE3	COMPLETED	Stem Cell Transplantation for Patients With Hematologic Malignancies
NCT00152594	PHASE3	TERMINATED	Voriconazole or Placebo in the Prophylaxis of Lung Infiltrates in Patients Undergoing Induction Chemotherapy for Acute Myelogenous Leukemia
NCT00186966	PHASE3	COMPLETED	Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia
NCT00226512	PHASE3	WITHDRAWN	To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning
NCT00260832	PHASE3	COMPLETED	Trial of Decitabine in Patients With Acute Myeloid Leukemia